Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,463 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis.
Menegaz de Almeida A, Oliveira P, Lopes L, et al. · Obstet Gynecol · 2025Systematic Review, Meta-Analysis
- Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer.
Cardoso F, Parke S, Brennan DJ, et al. · N Engl J Med · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lederman S, Ottery FD, Cano A, et al. · Lancet · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy of phytoestrogens for menopausal symptoms: a meta-analysis and systematic review.
Chen MN, Lin CC, Liu CF · Climacteric · 2015Meta-Analysis, Systematic Review
- Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
Johnson KA, Martin N, Nappi RE, et al. · J Clin Endocrinol Metab · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy of Micronized Progesterone for Sleep: A Systematic Review and Meta-analysis of Randomized Controlled Trial Data.
Nolan BJ, Liang B, Cheung AS · J Clin Endocrinol Metab · 2021Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy of plant-derived dietary supplements in improving overall menopausal symptoms in women: An updated systematic review and meta-analysis.
Oh MR, Park JH, Park SK, et al. · Phytother Res · 2024Meta-Analysis, Systematic Review
- Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial.
Panay N, Joffe H, Maki PM, et al. · JAMA Intern Med · 2025Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
de Oliveira HM, Diaz CAV, Barbosa LM, et al. · Maturitas · 2025Systematic Review, Meta-Analysis
- Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Manson JE, Chlebowski RT, Stefanick ML, et al. · JAMA · 2013Multicenter Study, Randomized Controlled Trial
- Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management.
van Beek AP, Emous M, Laville M, et al. · Obes Rev · 2017Systematic Review
- Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial.
Schaudig K, Wang X, Bouchard C, et al. · BMJ · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis.
Sánchez Martín MJ, Huerga López C, Cristóbal García I, et al. · Arch Gynecol Obstet · 2025Meta-Analysis, Review
- Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Neal-Perry G, Cano A, Lederman S, et al. · Obstet Gynecol · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education.
Bower JE, Partridge AH, Wolff AC, et al. · J Clin Oncol · 2021Clinical Trial, Phase III, Multicenter Study
- Objective and subjective vasomotor symptom outcomes in the CBT-Meno randomized controlled trial.
Green SM, Donegan E, McCabe RE, et al. · Climacteric · 2020Randomized Controlled Trial
- Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
Simon JA, Anderson RA, Ballantyne E, et al. · Menopause · 2023Randomized Controlled Trial
- Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.
Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. · JAMA Psychiatry · 2018Randomized Controlled Trial, Research Support, N.I.H., Extramural
- A Standardized Asparagus Racemosus Root Extract Improves Hormonal Balance and Menstrual Health and Reduces Vasomotor Symptoms in Perimenopausal Women: A Randomized, Double-Blind, Placebo-Controlled Study.
Yadav P, Yadav S, Vedururu SS, et al. · J Am Nutr Assoc · 2025Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy and Safety of Shatavari Root Extract in Managing Peri-Menopausal Symptoms-A Randomized, Double-Blind, Placebo Controlled Clinical Trial.
Surampalli G, S M, Mudhigonda M · J Diet Suppl · 2026Randomized Controlled Trial
- The efficacy of purified pollen extract for reducing vasomotor symptoms in women: a systematic review and meta-analysis.
Acquarulo EL, Hernandez EC, Kodzodziku F, et al. · Menopause · 2024Meta-Analysis, Systematic Review
- Acupuncture for menopausal hot flushes.
Dodin S, Blanchet C, Marc I, et al. · Cochrane Database Syst Rev · 2013Meta-Analysis, Systematic Review
- Resistance training decreased abdominal adiposity in postmenopausal women.
Nilsson S, Hammar M, West J, et al. · Maturitas · 2023Randomized Controlled Trial
- Vasomotor symptoms in women and cardiovascular risk markers: Systematic review and meta-analysis.
Franco OH, Muka T, Colpani V, et al. · Maturitas · 2015Meta-Analysis, Research Support, Non-U.S. Gov't
- Effects of exercise on vasomotor symptoms in menopausal women: a systematic review and meta-analysis.
Liu T, Chen S, Mielke GI, et al. · Climacteric · 2022Meta-Analysis, Systematic Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.